25299-26-7

Basic information

• Product Name: 3-bromo-5-chloro-2-methoxybenzaldehyde
• Synonyms: 3-bromo-5-chloro-2-methoxybenzaldehyde;OTAVA-BB 7020663682;3-bromo-5-chloro-2-methoxybenzaldehyde(SALTDATA: FREE)
• CAS NO: 25299-26-7
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.49
• Mol File: 25299-26-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 77 °C
• Boiling Point: 308.7°C at 760 mmHg
• Flash Point: 140.5°C
• Appearance: /
• Density: 1.628g/cm³
• Vapor Pressure: 0.000668mmHg at 25°C
• Refractive Index: 1.597
• CAS DataBase Reference: 3-bromo-5-chloro-2-methoxybenzaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 3-bromo-5-chloro-2-methoxybenzaldehyde(25299-26-7)
• EPA Substance Registry System: 3-bromo-5-chloro-2-methoxybenzaldehyde(25299-26-7)

Safety Data

• Hazardous Substances Data: 25299-26-7(Hazardous Substances Data)

Usage

InChI:InChI=1/C8H6BrClO2/c1-12-8-5(4-11)2-6(10)3-7(8)9/h2-4H,1H3

Upstream product

• 19652-32-5 3-bromo-5-chlorosalicylaldehyde 
• 74-88-4 methyl iodide 
• 65851-97-0 methyl 3-bromo-5-chloro-2-methoxybenzoate 
• 871339-17-2 [3-bromo-5-chloro-2-(methyloxy)phenyl]methanol 

Downstream Products

• 871339-18-3 3-bromo-5-chloro-2-(methyloxy)phenol 
• 938134-72-6 C₈H₇BrClNO₂ 
• 871339-19-4 2-{[3-bromo-5-chloro-2-(methyloxy)phenyl]oxy}-N,N-dimethylethanamine 
• 871339-20-7 2-{[5-chloro-2-(methyloxy)-3-piperazin-1-ylphenyl]oxy}-N,N-dimethylethanamine 
• 540778-98-1 ethyl (E)-5-bromo-3-chloro-6-methoxycinnamate 

Relevant articles and documents

Compounds and Methods for Inhibiting the Interaction of BCL Proteins with Binding Partners

The invention relates to isoxazolidine containing compounds that bind to bcl proteins and inhibit Bcl function. The compounds may be used for treating and modulating disorders associated with hyperproliferation, such as cancer.

Induction of apoptosis in cancer cells

The present invention provides compounds that are inducers or inhibitors of apoptosis or apoptosis preceded by cell-cycle arrest. In addition, the present invention provides pharmaceutical compositions and methods for treating mammals with leukemia or other forms of cancer or for treating disease conditions caused by apoptosis of cells.